Markets

Stoke Therapeutics is accelerating its Dravet syndrome drug development, aiming for a mid-2027 NDA submission for zorevunersen. The company is collaborating with Biogen on this RNA medicine designed to address the root cause of the severe epilepsy by restoring a key protein. Positive Phase 3 enrollment is on track, and Stoke is actively engaging with the FDA to expedite the drug’s availability for patients with limited options. The company has sufficient funding to support operations through 2028.

IDEAYA Biosciences unveiled its 2026 strategic roadmap, focusing on advancing its pipeline. Key objectives include presenting darovasertib trial results for uveal melanoma, potentially supporting accelerated approval, and initiating four registrational trials. The company will also advance its antibody-drug conjugate programs, including IDE849 for neuroendocrine cancers, and explore next-generation therapies targeting MTAP pathway alterations and CDKN2A. With substantial cash reserves extending into 2030, IDEAYA is set for significant pipeline progress and potential regulatory milestones.

Commerce has endorsed Google’s Universal Commerce Protocol (UCP), enabling direct purchasing across Google’s AI surfaces. This open standard aims to simplify integrations and create a smoother shopping journey from discovery to checkout. Commerce merchants will maintain “merchant of record” status, retaining control over transactions and customer data. This strategic move positions Commerce and its merchants to capitalize on the rise of AI-driven commerce.

Oracle has launched Oracle Retail Supply Chain Collaboration, a new cloud platform designed to enhance retailer resilience and efficiency. This AI-powered solution offers improved visibility, forecasts, and disruption alerts, streamlining communication with suppliers for better oversight, compliance, and risk mitigation. It integrates with Oracle Retail Merchandising Foundation Cloud Service, facilitating supplier assessments and data consolidation for more effective merchandising strategies.

Johnson & Johnson’s amivantamab combined with chemotherapy shows promising results in metastatic colorectal cancer. The bispecific antibody, targeting EGFR and MET, achieved a 51% overall response rate in RAS/BRAF wild-type patients. Longer-term data indicate sustained efficacy, with over 70% response in the first-line setting and durable responses exceeding two years. The combination also demonstrated activity in patients with liver metastases, with a 57% ORR. The safety profile was consistent with prior studies, with low discontinuation rates.

Oroco Resource Corp. is raising approximately C$20 million through a bought-deal offering of units to advance its copper-gold project in Mexico. Each unit includes a share and a warrant. Canaccord Genuity Corp. is leading the syndicate of underwriters. The funds will support exploration and development at the Santo Tomas Project, aiming to unlock its potential. This financing involves potential dilution for existing shareholders but offers future upside through warrants.

Foghorn Therapeutics secured $50 million in equity financing, extending its operational runway to mid-2028. This capital infusion will support the advancement of its oncology pipeline, including its lead program FHD-909, an oral SMARCA2 inhibitor for NSCLC, and novel degrader programs targeting CBP, EP300, and ARID1B. The financing, which includes common shares and warrants, was led by prominent biotech investors and signals strong confidence in Foghorn’s Gene Traffic Control® platform and innovative cancer therapies.

Summit Therapeutics has granted stock options to seventeen new employees, allowing them to purchase up to 214,331 shares at $18.66 each. These options have a ten-year term and vest over four years, designed to attract and retain talent in the competitive biopharmaceutical industry. This aligns employee interests with the company’s long-term growth and commitment to developing oncology therapies.

Ascendis Pharma unveiled an ambitious 2026 roadmap, projecting significant revenue growth driven by YORVIPATH and SKYTROFA. The company anticipates around €720 million in revenue for 2025 and aims for €500 million in operating cash flow by 2026. Key pipeline advancements include potential approval for TransCon CNP and promising combination therapies. Strategic collaborations and a $120 million share repurchase program underscore Ascendis’ transition to a global biopharma leader.

Main Street Financial Services Corp. is increasing its quarterly cash dividend by 7% to $0.15 per share, reflecting confidence in its financial stability and operational performance. The $1.5 billion holding company, with 20 branches across Ohio and West Virginia, attributes this hike to its strong banking franchise and customer trust. This move signals a positive outlook for investors seeking income, though the increase is a measured step.